Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function | PNAS
IJMS | Free Full-Text | Do Mutations Turn p53 into an Oncogene? | HTML
Frontiers | Promising New Tools for Targeting p53 Mutant Cancers: Humoral and Cell-Based Immunotherapies
TP53 mutation spectrum in primary colorectal cancers. a Proportion of... | Download Scientific Diagram
The cancer-associated, gain-of-function TP53 variant P152Lp53 activates multiple signaling pathways implicated in tumorigenesis - Journal of Biological Chemistry
IJMS | Free Full-Text | Targeting the Oncogenic p53 Mutants in Colorectal Cancer and Other Solid Tumors | HTML
Disarming mutant p53 oncogenic function - ScienceDirect
TP53 mutations as potential prognostic markers for specific cancers: Analysis of data from The Cancer Genome Atlas and the International Agency for Research on Cancer TP53 Database | bioRxiv
Systematic identification of mutations and copy number alterations associated with cancer patient prognosis | eLife
Analysis of P53 mutations and their expression in 56 colorectal cancer cell lines | PNAS
Prevalence of germline TP53 mutation among early onset middle eastern breast cancer patients | Hereditary Cancer in Clinical Practice | Full Text
Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma - Journal of Thoracic Oncology
The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases | Leukemia
Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma - eBioMedicine
High prevalence and allele burden-independent prognostic importance of p53 mutations in an inner-city MDS/AML cohort | Leukemia
Mutant p53 Drives Cancer Metastasis via RCP-Mediated Hsp90α Secretion - ScienceDirect
The TP53 mutation rate differs in breast cancers that arise in women with high or low mammographic density | npj Breast Cancer
Frontiers | Mutation-Derived Neoantigens for Cancer Immunotherapy
High prevalence of TP53 loss and whole-genome doubling in early-onset colorectal cancer | Experimental & Molecular Medicine
TP53 alterations of hormone-naïve prostate cancer in the Chinese population | Prostate Cancer and Prostatic Diseases
Time to first treatment and P53 dysfunction in chronic lymphocytic leukaemia: results of the O-CLL1 study in early stage patients | Scientific Reports
Mutant p53 elicits context-dependent pro-tumorigenic phenotypes | Oncogene
